In November 1988, the Food and Drug Administration (FDA) recommended that all blood donation centers screen blood supplies for HTLV-I antibodies. This is to prevent the transmission of HTLV-I infection to recipients of blood components. In August 15, 1997 FDA issued a Guidance for Industry, Donor Screening for Antibodies to HTLV-II for all donations of Whole Blood and blood components intended for use in transfusion and Source Leukocytes.
A study of 39,898 random blood donors in eight US cities showed that 10 (0.025%) were found to have antibodies against HTLV-I (Willams et al., 1988). This established the fact that HTLV-I infection might be transmitted to recipients via transfusion of cellular blood products from infected donors (Okochi et al, 1984). Since the recommendation by FDA, approximately 2,000 HTLV-I/II-infected blood donors were identified during the first year of screening in the United States. Further confirmatory test such as PCR were performed to differentiate between HTLV-I and HTLV-II infections. The results showed up to be approximately 50% with HTLV-I infections and 50% with HTLV-II infections. These donors were subsequently counseled and permanently deferred from donating blood.
The health information contained herein is provided for educational, reference purposes only, and is not intended to substitute professional medical advice, diagnosis, or treatment with a healthcare provider. All decisions regarding patient care must be made with a healthcare provider, considering the unique characteristics of the patient. Please check the availability and relevance of the information in your respective country.